Prothena Biosciences Limited

Elan Pharmaceuticals, Inc.

Othair Prothena Limited

Biogen Ma Inc.

Biogen Idec Ma Inc.

Other

Hoffmann-la Roche Inc.

Eli Lilly and Company

Novo Nordisk A/s

Neotope Biosciences Limited

Prothena Bioscience Limited

Robin McDaid Barbour

Tarlochan S Nijjar

Yue Liu

Philip James Dolan, Iii

Wagner Marcelo Zago

Svetlana Alexander

Dale Bernard Schenk

Meena Subramanyam

Eric M Wakshull

Frédérique Bard

Julie Elizabeth Taylor

Kate Dora Games Thiel

Michael Skov

Frances Lynn

Michael Panzara

Mark E Renz

Peter A Seubert

Peter Andrew Seubert

Carmen Vigo-Pelfrey

Gene Kinney

Lakshmi Amaravadi

Theodore A Yednock

Tamie Chilcote

Kenneth Flanagan

Stephen Jed Tam

Jeffrey N Higaki

Joshua Reginald Salmans

Mark D Welch

Olaf Mundigl

Sridhar Govindarajan

Jens Niewoehner

Georg Tiefenthaler

Philip W Payne

Tom Purcell

Deniz Kirik

Lynn R Zieske

Lakshimi Amaravadi

Sarah Hamren

Kelly L Johnson

Peter Seubert

Philip Payne

Shuning Gai

Kate Dora Games-Thiel

Jianmin Li

Tarlochan S Niijar

Dale B Shenk

Eric Wakshull

Philip James Iii Dolan

Natalie Regina Landeck

Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.

Anti-Aβ antibodies

The invention provides methods of detecting transthyretin (TTR) using a capture antibody and a reporter antibody. The capture antibody binds preferentially to misfolded TTR over native tetrameric form of TTR. The capture antibody binds to an epitope within amino acid residues 89-97 or TTR or to an epitope within amino acid residues 101-109 of TTR. 9D5 and 18C5 are examples of suitable capture antibodies. The methods can be used for diagnosing diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis) and for monitoring the efficacy of TTR therapies, among other applications.

Methods of detecting transthyretin

The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of Aβ and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide.

Multi-epitope vaccine for the treatment of Alzheimer's disease

The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

Tau immunotherapy

The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

Antibodies recognizing tau

The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).

Methods and products for evaluating an immune response to a therapeutic protein

Anti-abeta antibodies

Anti-Abeta antibodies

Growing community of inventors

Walnut Creek, CA, United States of America

Robin McDaid Barbour